KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Investing Activities (2016 - 2025)

Emergent BioSolutions' Cash from Investing Activities history spans 16 years, with the latest figure at -$3.9 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 113.64% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached $69.4 million, down 44.57%, while the annual FY2025 figure was $69.4 million, 44.57% down from the prior year.
  • Cash from Investing Activities reached -$3.9 million in Q4 2025 per EBS's latest filing, down from -$3.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $257.7 million in Q2 2023 to a low of -$271.6 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$9.9 million, with a median of -$13.2 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: plummeted 392.03% in 2022, then surged 902.8% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$45.8 million in 2021, then rose by 0.87% to -$45.4 million in 2022, then soared by 74.89% to -$11.4 million in 2023, then skyrocketed by 350.88% to $28.6 million in 2024, then crashed by 113.64% to -$3.9 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Cash from Investing Activities are -$3.9 million (Q4 2025), -$3.4 million (Q3 2025), and $17.2 million (Q2 2025).